Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference
Aldeyra Therapeutics (Nasdaq: ALDX), a biotechnology company focused on developing therapies for immune-mediated and metabolic diseases, has announced its participation in the 2025 Leerink Partners Global Healthcare Conference in Miami, Florida.
The company's President and CEO, Todd C. Brady, M.D., Ph.D., will engage in a fireside chat with Marc Goodman, Senior Managing Director, Neuroscience. The discussion is scheduled for Monday, March 10, 2025, at 9:20 a.m. ET.
Interested parties can access the live webcast through the Investors & Media section of Aldeyra's website. The webcast recording will remain available for 90 days following the event.
Aldeyra Therapeutics (Nasdaq: ALDX), un'azienda biotecnologica focalizzata nello sviluppo di terapie per malattie mediate dal sistema immunitario e metaboliche, ha annunciato la sua partecipazione alla 2025 Leerink Partners Global Healthcare Conference a Miami, Florida.
Il Presidente e CEO dell'azienda, Todd C. Brady, M.D., Ph.D., parteciperà a una chiacchierata informale con Marc Goodman, Direttore Senior, Neuroscienze. La discussione è prevista per lunedì 10 marzo 2025, alle 9:20 a.m. ET.
Le parti interessate possono accedere alla diretta streaming attraverso la sezione Investitori e Media del sito web di Aldeyra. La registrazione della diretta rimarrà disponibile per 90 giorni dopo l'evento.
Aldeyra Therapeutics (Nasdaq: ALDX), una empresa de biotecnología enfocada en el desarrollo de terapias para enfermedades mediadas por el sistema inmunológico y metabólicas, ha anunciado su participación en la 2025 Leerink Partners Global Healthcare Conference en Miami, Florida.
El Presidente y CEO de la empresa, Todd C. Brady, M.D., Ph.D., participará en una charla informal con Marc Goodman, Director Senior, Neurociencia. La discusión está programada para el lunes 10 de marzo de 2025, a las 9:20 a.m. ET.
Las partes interesadas pueden acceder a la transmisión en vivo a través de la sección de Inversores y Medios del sitio web de Aldeyra. La grabación de la transmisión estará disponible durante 90 días después del evento.
알데이라 치료제(Aldeyra Therapeutics) (Nasdaq: ALDX)는 면역 매개 및 대사 질환 치료제를 개발하는 생명공학 회사로, 플로리다주 마이애미에서 열리는 2025 리어링크 파트너스 글로벌 헬스케어 컨퍼런스에 참가한다고 발표했습니다.
회사의 회장 겸 CEO인 토드 C. 브래디, M.D., Ph.D.는 신경과학 수석 관리 이사인 마크 굿맨과 함께 대화에 참여할 예정입니다. 이 논의는 2025년 3월 10일 월요일 오전 9시 20분 ET에 예정되어 있습니다.
관심 있는 분들은 알데이라 웹사이트의 투자자 및 미디어 섹션을 통해 생중계를 시청할 수 있습니다. 생중계 녹화는 이벤트 후 90일 동안 이용 가능합니다.
Aldeyra Therapeutics (Nasdaq: ALDX), une entreprise de biotechnologie axée sur le développement de thérapies pour les maladies médiées par le système immunitaire et métaboliques, a annoncé sa participation à la 2025 Leerink Partners Global Healthcare Conference à Miami, en Floride.
Le Président et CEO de l'entreprise, Todd C. Brady, M.D., Ph.D., participera à une discussion informelle avec Marc Goodman, Directeur Général Senior, Neurosciences. La discussion est prévue pour le lundi 10 mars 2025, à 9h20 ET.
Les parties intéressées peuvent accéder à la diffusion en direct via la section Investisseurs et Médias du site Web d'Aldeyra. L'enregistrement de la diffusion sera disponible pendant 90 jours après l'événement.
Aldeyra Therapeutics (Nasdaq: ALDX), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Therapien für immunvermittelte und Stoffwechselerkrankungen konzentriert, hat seine Teilnahme an der 2025 Leerink Partners Global Healthcare Conference in Miami, Florida, angekündigt.
Der Präsident und CEO des Unternehmens, Todd C. Brady, M.D., Ph.D., wird an einem informellen Gespräch mit Marc Goodman, Senior Managing Director, Neurowissenschaften, teilnehmen. Die Diskussion ist für Montag, den 10. März 2025, um 9:20 Uhr ET angesetzt.
Interessierte Parteien können über den Bereich Investoren & Medien auf der Website von Aldeyra auf den Live-Stream zugreifen. Die Aufzeichnung des Streams bleibt 90 Tage nach der Veranstaltung verfügbar.
- None.
- None.
Dr. Brady’s conversation with Marc Goodman, Senior Managing Director, Neuroscience, is scheduled to begin at 9:20 a.m. ET Monday, March 10, 2025. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. Following the fireside chat, the webcast will be archived for 90 days.
About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250310401375/en/
Investor & Media Contact:
Laura Nichols
Tel: (781) 257-3060
investorrelations@aldeyra.com
Source: Aldeyra Therapeutics, Inc.
FAQ
When is Aldeyra Therapeutics (ALDX) presenting at the 2025 Leerink Partners Conference?
How can investors watch Aldeyra's (ALDX) presentation at the Leerink Conference?
What type of diseases does Aldeyra Therapeutics (ALDX) focus on treating?
Who will represent Aldeyra Therapeutics (ALDX) at the 2025 Leerink Conference?
